Powered By Bing

Mullighan Lab: Publications

2018

  • Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, Carroll A, Heerema NA, Zhang H, Moriyama T, Gastier-Foster JM, Xu H, Raetz E, Larsen E, Winick N, Bowman WP, Martin PL, Mardis ER, Fulton R, Zambetti G, Borowitz M, Wood B, Nichols KE, Carroll WL, Pui CH, Mullighan CG, Evans WE, Hunger SP, Relling MV, Loh ML, Yang JJ. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol. 2018;36(6):591-599

  • Welsh SJ, Churchman ML, Togni M, Mullighan CG, Hagman J. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis. Leukemia. 2018;32:38-48. Co-corresponding.

  • Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018;553:511-514.

  • Churchman ML, Qian M, te Kronnie G, Zhang R, Yang W, Zhang H, Lana T, Tedrick P, Baskin R, Verbist K, Peters J, Devidas M, Raetz E, Larsen E, Martin P, Bowman WP, Winick N, Mardis E, Fulton R, Stanulla M, Evans WE, Relling MV, Pui C-H, Hunger SP, Loh ML, Handgretinger R, Nichols K, Yang JJ, Mullighan CG. Germline IKZF1 variation and predisposition to acute lymphoblastic leukemia. Cancer Cell 2018;78:2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Co-corresponding author.

  • Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip JM, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Res. 2018;78:2747-2759. doi: 10.1158/0008-5472.CAN-17-1900

  • Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018;9:8027-41.

  • Milani G, Matthijssens F, Van Loocke W, Durinck K, Roels J, Peirs S, Thenoz M, Pieters T, Reunes L, Lintermans B, Vandamme N, Lammens T, Van Roy N, Van Nieuwerburgh F, Deforce D, Schwab C, Raimondi S, Dalla Pozza L, Carroll AJ, 3rd, De Moerloose B, Benoit Y, Goossens S, Berx G, Harrison CJ, Basso G, Cave H, Sutton R, Asnafi V, Meijerink J, Mullighan C, Loh M, Van Vlierberghe P. Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. Br J Haematol. 2018; in press doi: 10.1111/bjh.15425

  • KG Roberts, LJ Janke, Y Zhao, A Seth, J Ma, D Finkelstein, S Smith, K Ebata, BB Tuch, SP Hunger, CG Mullighan. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood 2018, in press. doi: 10.1182/blood-2018-05-849554

  • Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan CG, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Seigel M, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP. Dasatinib plus intensive chemotherapy in children, adolescents and young adults with Philadelphia chromosome positive acute lymphoblastic leukemia: Results of Children’s Oncology Group trial AALL0622. J Clin Oncol 2018; May 29:JCO2017767228. doi: 10.1200/JCO.2017.76.7228.

  • Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Li F, Chang F, Gu Z, Mullighan CG, Li Y, Harvey RC, Chen IM, Willman CL, Hunger SP, Li MM, Tasian SK. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematologica. 2018 May 17. pii: haematol.2018.192088. doi: 10.3324/haematol.2018.192088.

  • Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS, Kees UR. New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment. Leukemia. 2018. May 8. doi: 10.1038/s41375-018-0144-7

  • Heatley SL, Mullighan CG, Doherty K, Danner S, O'Connor GM, Hahn U, Szer J, Schwarer A, Bradstock K, Sullivan LC, Bardy PG, Brooks AG. Activating KIR Haplotype Influences Clinical Outcome Following HLA-Matched Sibling Hematopoietic Stem Cell Transplantation. HLA. 2018 Jun 25. doi: 10.1111/tan.13327.

  • Gu Z, Mullighan CG. ShinyCNV: a Shiny/R application to view and annotate DNA copy number variations. Bioinformatics. 2018:bty546-bty. https://doi.org/10.1093/bioinformatics/bty546

  • KG Roberts, SC Reshmi, RC Harvey, I-M Chen, K Patel, E Stonerock, H Jenkins, Y Dai, M Valentine, Z Gu, Y Zhao, Y Liu, Y Li, J Zhang, D Payne-Turner, M Devidas, NA Heerema, AJ Carroll, EA Raetz, MJ Borowitz, BL Wood, A Angiolillo, MJ Burke, WL Salzer, PA Zweidler-McKay, KR Rabin, L Mattano, KW Maloney, WL Carroll, ML Loh, CL Willman, JM Gastier-Foster, CG Mullighan, SP Hunger. Genomic and outcome analyses of Philadelphia chromosome-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood, 2018; in press. Co-corresponding author

  • Gloria M, Filip M, Wouter VL, Kaat D, Juliette R, Sofie P, Morgan T, Tim P, Lindy R, Beatrice L, Niels V, Tim L, Nadine VR, Filip VN, Dieter D, Claire S, Susana R, Luciano DP, J. CA, Barbara DM, Yves B, Steven G, Geert B, J. HC, Giuseppe B, Hélène C, Rosemary S, Vahid A, Jules M, Charles M, Mignon L, Pieter VV. Genetic characterization and therapeutic targeting of MYC‐rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology. 2018; in press http://dx.doi.org/10.1111/bjh.15425.

  • Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Zhou L, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang Y-L, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui C-H, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds SB, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG. The genetic basis and cell of origin of mixed phenotype acute leukemia. Nature 2018; in press

2017

  • Witkowski MT, Hu Y, Roberts KG, Boer JM, McKenzie MD, Liu GJ, Le Grice OD, Tremblay CS, Ghisi M, Willson TA, Horstmann MA, Aifantis I, Cimmino L, Frietze S, den Boer ML, Mullighan CG, Smyth GK, Dickins RA. Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome.J Exp Med 2017;214:773-791.

  • Konoplev S, Lu X, Konopleva M, Jain N, Ouyang J, Goswami M, Roberts KG, Valentine M, Mullighan CG, Bueso-Ramos C, Zweidler-McKay P, Jorgensen J, Wang SA. CRLF2-positive B acute lymphoblastic leukemia in adult patients: a single institution experience. Am J Clin Pathol 2017;147:357

  • Palacios G, Shaw TI, Li Y, Singh RK, Valentine M, Sandlund JT, Lim MS, Mullighan CG, Leventaki V. Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex. Leukemia. 2017;31:743-7.

  • Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang Y, Cheng C, Rambaldi A, Spinelli O, Radich J, Minden MD, Rowe JM, Luger S, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kantarjian HM, Konopleva M, Kornblau S, Paietta E, Willman CL, Mullighan CG. High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol; 2017;35:394-401. Corresponding author.

  • Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, Winick NJ, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J, Mullighan CG. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211-8. Co-corresponding author.

  • Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ, 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017;129:3352-61. Co-corresponding author.

  • Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017;23:e38-e45.

  • Smeenk L, Fischer M, Jurado S, Jaritz M Azaryan A, Werner B, Roth M, Zuber J, Stanulla M, den Boer ML, Mullighan CG, Strehl S, Busslinger M. Molecular role of the PAX5-ETV6 oncoprotein in promoting B cell acute lymphoblastic leukemia. EMBO J 2017;36:718-735

  • Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572-581

  • Gadd S, Huff V, Walz AL, Ooms A, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Hermida LC, Davidsen T, Gesuwan P, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Dome JS, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Ross N, Gastier-Foster JM, Arold ST, Perlman EJ. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017;49:1487-94.

  • Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Dalla Pozza L, Yeung DT, Sutton R, White DL. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica. 2017;102:e490-493

  • Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. 2017;102:e514-e517

  • Sewastianik T, Jiang M, Sukhdeo K, Patel SS, Roberts K, Kang Y, Alduaij A, Dennis PS, Lawney B, Liu R, Song Z, Xiong J, Zhang Y, Lemieux ME, Pinkus GS, Rich JN, Weinstock DM, Mullighan CG, Sharpless NE, Carrasco RD. Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Adv. 2017;1:2361-2374.

  • Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, Song G, Wu G, Easton J, Kesserwan C, Nichols KE, Mullighan CG, Ribeiro RC, Klco JM. The Genomic Landscape of Pediatric Myelodysplastic Syndromes. Nat Commun 2017;8:1557

  • Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T. Drugging DNA repair to target T-ALL cells. Leuk Lymphoma. 2017:1-4.

  • Budhraja A, Turnis ME, Churchman ML, Kothari A, Yang X, Xu H, Kaminska E, Panetta JC, Finkelstein D, Mullighan CG, Opferman JT. Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 15;23:7558-7568

  • Roberts KG, Yang Y-L, Payne-Turner D, Lin W, Files JK, Dickerson K, Gu Z, Taunton J, Janke LJ, Chen T, Loh ML, Hunger SP, Mullighan CG. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Advances. 2017;1:1657-71. Corresponding author.

2016

  • Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 2016;29:186-200. Corresponding author.

  • Perlman EJ, Gadd S , Arold ST, Radhakrishnan A, Gerhard DS, Jennings L, Huff V, Guidry Auvil JM, Davidsen TM, Dome JS, Meerzaman D, Hsu CH, Nguyen C, Anderson J, Ma Y, Mungall AJ, Moore RA, Marra MA, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Gastier-Foster JM, Ross N, Smith MA. MLLT1 (ENL) YEATS Domain Mutations in Clinically Distinctive Favorable Histology Wilms Tumors. Nat Commun 2015 Dec 4;6:10013.

  • Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts K, Waanders E, Choi J, Ma X, Raimondi S, Fan Y, Yang W, Song G, Yang J, Inaba H, Downing J, Leung W, Bowman WP, Relling M, Evans W, Zhang J, Campana D, Pui CH. Outcome of Children with Hypodiploid ALL Treated with Risk-directed Therapy Based on MRD Levels. Blood 2015;126(26):2896-9. First and co-corresponding author.

  • Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Martin MS, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Amstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M. Tumor-Specific HSP90 Inhibition as a Therapeutic Approach in JAK-Mutant Acute Lymphoblastic Leukemias. Blood 2015;126(22):2479-83. 

  • Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, Yang W, Cheng C, Cao X, Quinn E, Raimondi S, Gastier-Foster JM, Elizabeth E, Larsen E, Martin P, Bowman WP, Winick N, Komada Y, Wang S, Edmonson M, Xu H, Mardis E, Fulton R, Pui C-H, Mullighan CG, Evans WE, Zhang J, Hunger SP, Relling MV, Nichols KE, Loh ML, Yang JJ. Germline Genetic Variation in ETV6 and Risk of Childhood Acute Lymphoblastic Leukemia: a Systematic Genetic Study. Lancet Oncol 2015;16(16):1659-66.

  • He J, Abdel-Wahab O, Nahas M, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Knapp ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan CG, Dogan A, Armstrong SA, Mughal T, Vergilio J, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MRM, Otto GA, Lipson D, Levine RL. Integrated Genomic DNA/RNA Profiling of Hematologic Malignancies in the Clinical Setting. Blood 2016;127(24):3004-14.

  • Pang SH, Minnich, Gangatirkar P, Zheng Z, Ebert A, Song G, Dickins RA, Corcoran LM, Mullighan CG, Busslinger M, Huntington ND, Nutt SL, Carotta S. PU.1 cooperates with IRF4 and IRF8 to suppress pre-B cell leukemia. Leukemia. 2016 Jun;30(6):1375-87. 

  • Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl C, Ness SA, Rusch M, Li Y, Onozawa M, Martinez C, Wood B, Asselin B, Chen I-M, Roberts K, Baruchel A, Soulier J, Dombret H, Zhang J, Larson R, Raetz E, Carroll W, Winick N, Aplan P, Loh M, Mullighan CG, Hunger SP, Heerema NA, Carroll A, Dunsmore K, Winter S. MLL Rearrangements Impact Outcome in HOXA-deregulated T-lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Leukemia 2016;Sep;30(9):1909-12.

  • DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA,  Bloomfield CD, Geyer S Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 2016;18:1-9.

  • Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Falkenburg JH, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica 2016;101:1082-93

  • Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG. Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL. JCI Insight 2016;1(4). pii: e86082. Corresponding author.

  • Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L, Zhang J, Klco JM, Downing JR. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48(12):1551-1556.

  • Zhang J, McCastlain K, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Xu B, Wen J, Edmonson M, Payne-Turner D, Yoshihara H, Chang Y, Churchman ML, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder H, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrozek K, Paietta E, Tallman MS, Stock W, Voorhees PM, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Hunger SP, Loh ML, Downing JR, Mullighan CG for the St Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016;48(12):1481-1489. Co-corresponding author.

  • Gu Z, Li Y, Liu Y, Reshmi SC, Roberts KG, Harvey RC, McCastlain M, Payne-Turner D, Churchman M, Iacobucci I, Shao Y, Chen I-M, Valentine M, Pei D, Mungall K, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood BL, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD,  Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukemia. Nat Commun 2016;7:13331 doi:10.1038/ncomms13331. Corresponding author.

  • Ooms AH, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen QR, Hsu CH, Yan C, Nguyen C, Hu Y, Ma Y, Zong Z, Mungall AJ, Moore RA, Marra MA, Huff V, Dome JS, Chi YY, Tian J, Geller JI, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Walz AL, van den Heuvel-Eibrink MM, de Krijger RR, Ross N, Gastier-Foster JM, Perlman EJ. Clin Cancer Res. 2016: in press. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res 2016;22(22):5582-5591

  • Herold T, Schneider S, Metzeler K, Neumann M, Hartmann L, Roberts KG, Konstandin NP, Greif PA, Bräundl K, Ksienzyk B, Huk N, Schneider I, Zellmeier E, Jurinovic V, Mansmann U, Hiddemann W, Mullighan CG, Bohlander SK, Spiekermann K, Hölzer D, Brüggemann M, Baldus CD, Dreyling M, Gökbuget N. Philadelphia chromosome-like acute lymphoblastic leukemia in adults have frequent IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2017;102:130-138 

  • Yang W, Wu G, Broeckel U, Smith CA, Turner V, Haidar CE, Wang S, Carter R, Karol SE, Neale G, Crews K, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV. Comparison of Genome Sequencing and Clinical Genotyping for Pharmacogenes. Clinical Pharmacology and Therapeutics. 2016;100:380-8

2015

  • Theocharides APA, Dobson SM, Laurenti E, Notta F, Voisin V, Cheng P-Y, Minden MD, Mullighan CG, Torlakovic E, Dick JE. Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts. Leukemia 2015;29(1):177-87.

  • Holmfeldt L, Mullighan CG. Generation of Human Acute Lymphoblastic Leukemia Xenografts for Use in Oncology Drug Discovery. Current Protocols in Pharmacology; 2015;68:14.32.1-14.32.19. Corresponding author.

  • Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan CG, Hughes TP, White DL. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia 2015;29(1):230-2.

  • Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng I-M, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrozek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Yue F, Wang Y, Pui C-H, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG*, Yang JJ*. A Genome-wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood. 2015;125(4):680-6. *co-corresponding

  • Andersson AK, Ma J, Wang J, Chen X, Larson-Gedman A, Dang J, Nakitandwe J, Holmfeldt L, Parker M, Easton J, Huether R, Kriwacki R, Rusch M, Wu G, Mulder H, Raimondi S, Pounds S, Guolian K, Shi L, Becksfort, Gupta P, Payne-Turner D, Vadodaria B, Manne J, Song G, Edmonson M, Nagawatte P, Wei L, Cheng C, Pei D, Sutton R, Venn NC, Chetcuti A, Rush A, Catchpoole D, Heldrup J, Fioretos T, Lu C, Ding L, Pui C-H, Shurtleff S, Gruber TA, Mullighan CG, Mardis ER, Wilson RK, Zhang J, Downing JR, for the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project. The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias. Nat Genet 2015;47:330-7.

  • Walz A, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen Q-R, Hsu QH, Yan C, Nguyen C, Hu Y, Bowlby R, Brooks D, Ma Y, Mungall AJ, Moore RA, Schein J, Marra MA, Huff V, Dome JS, Chi Y-Y, Mullighan CG, Ma J, Wheeler DA, Hampton OA, Jafari  N, Ross N, Gastier-Foster JM, Perlman EJ. Recurrent Somatic and Germline DGCR8, DROSHA, XPO5, DICER1, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. Cancer Cell 2015;27:286-97

  • Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125(11):1759-1767.

  • Suryani S, Bracken LS, Harvey RC, Sia KCS, Carol H, Chen I-M, Evans K, Dietrich P, Roberts KG, Kurmasheva RT, Billups C, Mullighan CG, Willman CL, Hunger SP, Houghton PJ, Smith MA, Lock RB. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Molecular Cancer Therapy. 2015;14(2):364-74.

  • Paugh SW, Bonten EJ, Savic D,  Ramsey LB, Thierfelder WE, Gurung P, Subbarao Malireddi RK, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, Fan Y, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeldt L, Mullighan CG, den Boer ML, Pieters R, Jeha S,  Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui C-H, Myers RM, Guy RK, Kanneganti T-D, Relling MV, Evans WE. NALP3 inflammasome up-regulation and CASP1 cleavage of the glucocorticoid receptor causes glucocorticoid resistance in leukemia cells. Nat Genet 2015;47(6):607-14

  • Chen X, Gupta P, Wang J, Nakitandwe J, Roberts K, Dalton JD, Parker M, Patel S, Holmfeldt L, Payne D, Easton J, Ma J, Rusch M, Wu G, Patel A, Dyer M, Shurtleff S, Espey S, Pounds S, Downing J, Ellison D, Mullighan C, Zhang J. CONSERTING: an accurate method for detecting somatic DNA copy number alterations in whole genome sequencing data. Nat Methods, 2015;12(6):527-30.

  • Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. J Hematol Oncol. 2015;8(1):39.

  • Dang J, Wei L, de Ridder J, Su X, Rust AG, Roberts KG, Payne-Turner D, Cheng J, Ma J, Qu C, Wu G, Song G, Huether R, Schulman B, Janke L, Zhang J, Downing JR, van der Weyden L, Adams DJ, Mullighan CG. Pax5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood 2015;125(33):3609-17. Corresponding author.

  • Ma X, Edmonson M, Yergeau D, Muzny D, Hampton OA, Rusch M, Song G, Easton J, Harvey RC, Wheeler DA, Ma J, Doddapaneni H, Vadodaria B, Wu G, Nagahawatte P, Carroll WL, Chen I-M, Gastier-Foster JM,  Relling MV, Smith MA, Devidas M, Guidry Auvil JM, Downing JR, Loh ML, Willman CL, Gerhard DL, Mullighan CG*, Hunger SP* and Zhang J*. The Rise and Fall of Subclones from Diagnosis to Relapse in Pediatric B-progenitor Acute Lymphoblastic Leukemia. Nat Commun 2015;6:6604.  *co-corresponding

  • Gooskens SL, Gadd S, Auvil JG, Gerhard DS, Khan J, Patidar R, Meerzaman D, Chen Q-R, Hsu CH, Yan C, Nguyen C, Hu Y, Mullighan CG, Ma J,  de Krijger R, van den Heuvel-Eibrink MM, Smith MA, Ross NA, Gastier-Foster JM, Perlman EJ. TCF21 hypermethylation in genetically quiescent Clear Cell Sarcoma of the Kidney. Oncotarget 2015;6(18):15828-41.

  • Topka S, Vijai, Walsh MF, Jacobs L, Maria A, Villano D1, Gaddam P, Wu G, McGee RB, Quinn E, Inaba H, Hartford C2, Pui CH, Pappo AS, Edmonson M, Zhang M, Stepensky P, Steinherz P, Schrader K, Lincoln A, Bussel J, Lipkin S, Goldgur Y, Harit M, Stadler ZK, Mullighan C, Weintraub M, Shimamura A, Zhang J, Downing JR, Nichols KE, Offit K. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet 2015 Jun 23;11(6):e1005262.

  • Churchman ML, Low J, Qu C, Paietta EM, Kasper LH, Chang Y, Payne-Turner D, Althoff MJ, Song G, Chen S-C, Ma J, Rusch M, McGoldrick D, Edmonson M, Gupta P, Wang Y-D, Caufield W, Freeman B, Li L, Panetta JC, Baker S, Yang Y-L, Roberts K, McCastlain K, Iacobucci I, Peters JL, Centonze VE, Notta F, Dobson SM, Zandi S, Dick JE, Janke L, Peng J, Kodali K, Pagala V, Min J, Mayasundari A,  Williams RT, Willman CL, Rowe J, Luger S, Dickins RA, Guy RK, Chen T, Mullighan CG. Efficacy of Retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell 2015;28(3):343-56. Corresponding author.

  • Xu H, Zhang H, Yang W, Yadav R, Morrison AC, Qian M, Devidas M, Liu Y, Perez-Andreu V, Zhao X, Gastier-Foster JM, Lupo PJ, Neale G, Raetz E, Larsen E, Bowman WP, Carroll WL, Winick N, Williams R, Hansen T, Holm J-C, Mardis E, Fulton R, Pui C-H, Zhang J, Mullighan CG, Evans WE, Hunger SP, Gupta R, Schmiegelow K, Loh ML, Relling MV, Yang JJ.  Inherited Coding Variants at the CDKN2A Locus Influence Susceptibility to Acute Lymphoblastic Leukemia in Children. Nat Commun 2015 Jun 24;6:7553.

  • Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, Karol SE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015;126(1):69-75.